EP0663822A4 - Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine. - Google Patents

Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine.

Info

Publication number
EP0663822A4
EP0663822A4 EP93922832A EP93922832A EP0663822A4 EP 0663822 A4 EP0663822 A4 EP 0663822A4 EP 93922832 A EP93922832 A EP 93922832A EP 93922832 A EP93922832 A EP 93922832A EP 0663822 A4 EP0663822 A4 EP 0663822A4
Authority
EP
European Patent Office
Prior art keywords
nitrendipine
angina
disorders
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93922832A
Other languages
German (de)
French (fr)
Other versions
EP0663822A1 (en
Inventor
Timothy J Barberich
James W Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of EP0663822A1 publication Critical patent/EP0663822A1/en
Publication of EP0663822A4 publication Critical patent/EP0663822A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
EP93922832A 1992-10-06 1993-10-05 Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine. Withdrawn EP0663822A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95720092A 1992-10-06 1992-10-06
US957200 1992-10-06
PCT/US1993/009463 WO1994007476A1 (en) 1992-10-06 1993-10-05 Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine

Publications (2)

Publication Number Publication Date
EP0663822A1 EP0663822A1 (en) 1995-07-26
EP0663822A4 true EP0663822A4 (en) 1997-04-23

Family

ID=25499221

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93922832A Withdrawn EP0663822A4 (en) 1992-10-06 1993-10-05 Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine.

Country Status (5)

Country Link
EP (1) EP0663822A4 (en)
JP (1) JPH08502263A (en)
AU (1) AU5170393A (en)
CA (1) CA2146545A1 (en)
WO (1) WO1994007476A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4613496B2 (en) * 2003-02-07 2011-01-19 味の素株式会社 Arrhythmia treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0381262A (en) * 1989-08-23 1991-04-05 Yamanouchi Pharmaceut Co Ltd Production of optically active substance of dihydropyridine-based calcium antagonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2117571C3 (en) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Asymmetrical 1,4-dihydropyridine-33-dicarboxylic acid esters, process for their preparation and their use as pharmaceuticals
GB1552911A (en) * 1975-07-02 1979-09-19 Fujisawa Pharmaceutical Co 1,4 dihydropyridine derivatives and the preparation thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0381262A (en) * 1989-08-23 1991-04-05 Yamanouchi Pharmaceut Co Ltd Production of optically active substance of dihydropyridine-based calcium antagonist

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ELTZE ET AL.: "Stereoselective Inhibition of Thromboxane-Induced Coronary Vasoconstriction by 1,4-dihydropyridine Calcium Channel Antagonists", CHIRALITY, vol. 2, no. 4, 1990, pages 233 - 240, XP000616626 *
HOELTJE ET AL.: "Qualitative and Quantitative Structure-Activity Relationship for Calcium Channel Modulating 1,4-Dihydropyridine Derivatives: A Hypothetical Molecular Receptor Model", QUANT. STRUCT. ACT. RELAT., vol. 7, no. 3, 1988, pages 174 - 178, XP000616609 *
MAST ET AL.: "Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers.", BR. J. CLIN. PHARMAC., vol. 33, no. 1, 1992, pages 51 - 59, XP000617464 *
PATENT ABSTRACTS OF JAPAN vol. 015, no. 252 (C - 0844) 26 June 1991 (1991-06-26) *
See also references of WO9407476A1 *
STRIESSNIG ET AL.: "Human red-blood-cell Ca2+-antagonist binding sites", EUR. J. BIOCHEM., vol. 150, no. 1, 1985, pages 67 - 77, XP000616619 *

Also Published As

Publication number Publication date
AU5170393A (en) 1994-04-26
JPH08502263A (en) 1996-03-12
CA2146545A1 (en) 1994-04-14
EP0663822A1 (en) 1995-07-26
WO1994007476A1 (en) 1994-04-14

Similar Documents

Publication Publication Date Title
EP0661970A4 (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine.
AU6904498A (en) Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
PL324313A1 (en) 10-axcyloxy 10,11-dihydrobenz/b,f/azepin-5-carboxyamides useful in treating nervous system disorders
AU4073997A (en) 1,4-heterocyclic metallprotease inhibitors
HUP0001237A3 (en) Methods for treating vascular disorders
EP0647134A4 (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine.
AU2287495A (en) Methods and compositions for treating depression and other disorders using optically pure s(+) fluoxetine
HUP0003964A2 (en) Methods for treating thrombotic disorders
AU2054297A (en) Suture collet
SI0908458T1 (en) Substituted pyridylmethylpiperazine and piperidine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
AU5652698A (en) (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
EP0920419A4 (en) Compounds, compositions and methods for treating influenza
AU3682995A (en) Wood chip strand splitter
HUP0100640A3 (en) Process for the preparation of 1,4-dihydropyridines
AU3271593A (en) Inlay, inlay holder, method for tooth restoration, and tooth restoration set for carrying out the method
HUP0003488A3 (en) Methods and compsitions for treating pulmonary disorders using optically pure (s)-salmeterol
AU1860995A (en) Quinoline or quinazoline derivatives as anti-inflammatory agents, in particular for treating arthritis
AU3245593A (en) Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
EP0700292A4 (en) Methods and compositions for treating gastric disorders using optically pure (+) pantoprazole
EP0711159A4 (en) Methods and compositions for treating asthma, atherosclerosis andinflammatory diseases using optically pure (-)-zileuton
AU4178497A (en) HTm4, methods of treatment and assays, agonists and antagonists
EP0663822A4 (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine.
AU4103097A (en) Tip resistant bottle filter
EP0661971A4 (en) Methods and compositions for treating hypertension, angina, and other disorders using optically pure s(-) felodipine.
GB0108236D0 (en) Formation treatment method using deformable particles

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950427

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970306

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980813

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991214